Last reviewed · How we verify

NCT00001260

Brain Tissue Collection for Neuropathological Studies

Terminated Last updated 9 December 2019
What this trial tests

trial in Bipolar Disorder in 2,161 participants. Terminated before completion.

Timeline
29 May 1990
16 June 2017

Quick facts

Lead sponsorNational Institute of Mental Health (NIMH)
StatusTerminated
Study typeOBSERVATIONAL
Enrollment2,161
Start date29 May 1990
Estimated completion16 June 2017
Sites3 locations across United States

Conditions studied

Sponsor

National Institute of Mental Health (NIMH)

Who can join

Eligibility, any sex, with Bipolar Disorder or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to collect and study the brain tissue of deceased individuals to learn more about the nervous system and mental disorders. Information gained from donated tissue may lead to better treatments and potential cures for nervous system and mental disorders. This study will ask relatives of deceased individuals to donate the brains of their deceased relatives to allow further study of neurological and psychiatric disorders. We do not accept prospective donations.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex and Co-localization with Schizophrenia GWAS.
    Dobbyn A, Huckins LM, Boocock J, Sloofman LG, et al · · 2018 · cited 137× · PMID 29805045 · DOI 10.1016/j.ajhg.2018.04.011
  2. The Gene Encoding Protocadherin 9 (PCDH9), a Novel Risk Factor for Major Depressive Disorder.
    Xiao X, Zheng F, Chang H, Ma Y, et al · · 2018 · cited 44× · PMID 28990594 · DOI 10.1038/npp.2017.241
  3. Temporal dynamics of miRNAs in human DLPFC and its association with miRNA dysregulation in schizophrenia.
    Hu Z, Gao S, Lindberg D, Panja D, et al · · 2019 · cited 39× · PMID 31431609 · DOI 10.1038/s41398-019-0538-y
  4. DLPFC transcriptome defines two molecular subtypes of schizophrenia.
    Bowen EFW, Burgess JL, Granger R, Kleinman JE, et al · · 2019 · cited 31× · PMID 31073119 · DOI 10.1038/s41398-019-0472-z
  5. The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders.
    Mansur RB, Fries GR, Trevizol AP, Subramaniapillai M, et al · · 2019 · cited 24× · PMID 30409537 · DOI 10.1016/j.euroneuro.2018.10.007
  6. Analysis of gene expression in the postmortem brain of neurotypical Black Americans reveals contributions of genetic ancestry.
    Benjamin KJM, Chen Q, Eagles NJ, Huuki-Myers LA, et al · · 2024 · cited 23× · PMID 38769152 · DOI 10.1038/s41593-024-01636-0
  7. Expression of dopamine signaling genes in the post-mortem brain of individuals with mental illnesses is moderated by body mass index and mediated by insulin signaling genes.
    Mansur RB, Fries GR, Subramaniapillai M, Frangou S, et al · · 2018 · cited 20× · PMID 30391805 · DOI 10.1016/j.jpsychires.2018.10.020
  8. Coordinated Expression of Phosphoinositide Metabolic Genes during Development and Aging of Human Dorsolateral Prefrontal Cortex.
    Rapoport SI, Primiani CT, Chen CT, Ahn K, et al · · 2015 · cited 18× · PMID 26168237 · DOI 10.1371/journal.pone.0132675

Verify or expand the search:

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

Other National Institute of Mental Health (NIMH) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing